Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection

Journal of Infectious Diseases

Volumn 210, Issue 7, 2014, Pages 1042-1046

  Vaidya, Sagar A ^a,b   Korner, Christian ^a   Sirignano, Michael N ^a   Amero, Molly ^a   Bazner, Sue ^b   Rychert, Jenna ^b   Allen, Todd M ^a   Rosenberg, Eric S ^c   Bosch, Ronald J ^c   Altfeld, Marcus ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Disease progression; HIV AIDS; Inflammation; TNF ; Viral load set point

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; VIRUS INHIBITION; VIRUS LOAD; ADULT; BLOOD; COHORT ANALYSIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; VIROLOGY;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 84908471773     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu206     Document Type: Article

References (15)

1. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012;55:126-36.
2. Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev 2012;23:193-206.
3. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006;22:757-62.
4. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012;205(Suppl 3):S375-82.
5. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
6. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-90.
7. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013;21:6-13.
8. Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006;42:1024-31.
9. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.
10. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-7.
11. Freiberg MS, Chang CC, Kuller LH, et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Intern Med 2013;173:614-22.
12. Miedema F, Hazenberg MD, Tesselaar K, Van Baarle D, De Boer RJ, Borghans JA. Immune Activation and Collateral Damage in AIDS Pathogenesis. Front Immunol 2013;4:298.
13. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996;10:F45-50.
14. Liovat AS, Rey-Cuille MA, Lecuroux C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012;7:e46143.
15. Tabb B, Morcock DR, Trubey CM, et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013;207:880-92.